Navigation Links
New England Biolabs Launches NEBNext™ Quick DNA Sample Prep Reagent Sets for Use With Roche/454 Next Generation Sequencing Platforms
Date:7/13/2010

IPSWICH, Mass., July 13 /PRNewswire/ -- New England Biolabs (NEB) has expanded its line of reagents for sample preparation with the introduction of NEBNext™ Quick DNA Sample Prep Reagent Set 2 and Master Mix Set 2, both suitable for library construction for Roche's 454 GS FLX Titanium™ and GS Junior™ instruments. These new products provide all the necessary enzymes and buffers for fast fragment library preparation. The Master Mix Set further streamlines the workflow, reducing the number of vials by one third.

(Logo: http://photos.prnewswire.com/prnh/20090921/NE79207LOGO-b )

(Logo: http://www.newscom.com/cgi-bin/prnh/20090921/NE79207LOGO-b )

NEBNext products are a series of highly pure reagents that facilitate sample preparation for downstream applications, such as next generation sequencing. All reagents undergo stringent quality controls and functional validation by sequencing, ensuring maximum yield, convenience and value. Reagents are now available for each step of the library construction workflow, including end-repair, dA-tailing, adapter ligation and amplification. Available as reagent sets, master mixes or modules for the three leading next generation sequencing platforms, the full range of NEBNext reagents offer convenience and customization of workflow. Additionally, NEB offers NEBNext™ dsDNA Fragmentase™, an enzyme-based solution for fragmentation of DNA.

For more information, visit www.NEBNext.com.

About NEB

Established in mid 1970's, New England Biolabs, Inc. is the industry leader in the discovery and production of enzymes for molecular biology applications and now offers the largest selection of recombinant and native enzymes for genomic research. NEB continues to expand its product offerings into areas related to PCR, gene expression, cellular analysis and RNA analysis. Additionally, NEB is focusing on strengthening alliances that enable new technologies to reach key market sectors. New England Biolabs is a privately held company, headquartered in Ipswich, MA and has extensive worldwide distribution through a network of exclusive distributors, agents and five subsidiaries located in Canada, China, Germany, Japan and the UK. For more information about New England Biolabs visit www.neb.com.

454, GS FLX Titanium and GS Junior are trademarks of Roche.


'/>"/>
SOURCE New England Biolabs
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. The New England Journal of Medicine Publishes Results of Landmark CREST Study, Showing Similar Positive Outcomes for Abbotts Carotid Stent System and Surgery
2. Whistleblower Lawyers Comment on New England Journal of Medicine Study
3. STELARA(TM) Shows Greater Efficacy Than Etanercept for Treatment of Moderate to Severe Plaque Psoriasis: Phase 3 Comparator Study Published in The New England Journal of Medicine
4. Millennium Pharmacy Adds First Client in New England
5. BioSpecifics Technologies Corp. Announces XIAFLEX(TM) CORD I Study Published in New England Journal of Medicine
6. Potential Skin Cancer Breakthrough Tested at Scottsdale Healthcare Published Today in New England Journal of Medicine
7. Results In The New England Journal Of Medicine Confirm Novartis Drug Femara(R) Is Superior To Tamoxifen After Breast Cancer Surgery
8. Orameds Chief Scientific Officer, Miriam Kidron, Ph.D., Chosen to Lecture at the 2009 British Pharmaceutical Conference in Manchester, England
9. Studies Published in the New England Journal of Medicine Highlight Potential New Option in the Treatment of Bone Loss
10. SCAI Statement on the BARI 2D Trial (Bypass Angioplasty Revascularization Investigation With Diabetes Trial) Presented at the American Diabetes Association (ADA) Annual Scientific Sessions and Published in The New England Journal of Medicine
11. Study in the New England Journal of Medicine Shows Non-Surgical Treatment for Pre-Cancerous Condition of Esophagus is Effective and Reduces Risk for Cancer Development
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... DUBLIN , May 5, 2016 ... Markets has announced the addition of the  ... Highlights - 2016"  report to their ... http://photos.prnewswire.com/prnh/20160330/349511LOGO ) , ,The latest ... Landscape Highlights - 2016, provides comprehensive ...
(Date:5/5/2016)... , May 5, 2016 ... the addition of the  "Europe Thrombocytopenia ... 2016"  report to their offering.  ... ) , ,The latest research Europe ... - 2016, provides comprehensive insights into ...
(Date:5/5/2016)... , May 5, 2016 ... addition of the  "Europe Thalassaemia Market and ... their offering.       (Logo: ... Europe Thalassaemia Market and Competitive Landscape Highlights ... pipeline products, Thalassaemia epidemiology, Thalassaemia market valuations ...
Breaking Medicine Technology:
(Date:5/5/2016)... ... May 05, 2016 , ... ... human health, today GrassrootsHealth, a public health promotion and research organization, declared May ... a technology-driven society, and other shifts in cultural behavior over the past several ...
(Date:5/4/2016)... ... May 05, 2016 , ... The talus is the part ... like falls, or traffic accidents can cause the talus bone to be fractured, and ... bone. In a first-of-its-kind procedure using 3D printing technology, internationally renowned orthopedic surgeon ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... donated 100 of its innovative kicking trainers to St. Jude Children’s Research Hospital ... is a durable, lightweight rubber band designed to teach children how to kick ...
(Date:5/4/2016)... ... May 04, 2016 , ... ... Camas and Vancouver, WA, has announced the latest beneficiary of their ongoing ... Foundation and their Mammography Program, which provides free mammograms and diagnostic breast ...
(Date:5/4/2016)... , ... May 04, 2016 , ... ... products, announced today the introduction of the innovative newly improved Iso-Hip Wrap. ... replacement patients. The plush design enhances comfort and enables the patient to enjoy ...
Breaking Medicine News(10 mins):